Assessing the Viability of FDA’s Biosimilars Pathway
Couldn’t attend the event? Check out some of our speakers’ slide presentations! Description The 2010 passage of the Biologics Price Competition and Innovation Act was intended to create a pathway for the approval of biosimilar drugs, to bring to market less expensive versions of innovators’ biologic therapeutics in the same way the Hatch-Waxman Act has…